PERSONAL INFORMATION

Name: **Davide Brusa**

Institution: Institute of Experimental and Clinical Research (IREC)
Université Catholique de Louvain (UCL)
Avenue Hippocrate, 55 bte B1.55.20 (55+2) - 1200 Brussels - BELGIUM
Tel: 32.2.764.55.63

E-mail: davide.brusa@uclouvain.be

EDUCATION

- 2000-2003: Bachelor Degree in Biotechnology, University of Turin. Supervisor: Prof. Lina Matera, PhD.
- 2003-2005: Master Degree in Medical Biotechnology, University of Turin. Supervisor: Prof. Lina Matera, PhD.
- 2005-2009: Ph.D. in Biochemistry and Cellular Biotechnology, University of Turin. Supervisor: Lina Matera, PhD.
- 2010-2011: Graduated in Biomedical Laboratory Diagnostic Techniques, Faculty of Medicine, University of Rome "Tor Vergata". Supervisor: Prof. Sergio Bernardini, MD.
- 2015: board certification for flow cytometry and cell sorting, Italian Society for Cytometry (GIC)

CURRENT POSITION

Principal Research Logistician (Logisticien de Recherche Principal) of the Flow Cytometry and Cell Sorting Platform at IREC Institution, UCLouvain, Brussels.

Belgian Society for Advanced Cytometry Board member.

PREVIOUS POSITIONS

- 2003-2005: Internal student, Master degree thesis title: "Generation of cytotoxic antitumor response against urologic tumors" (Laboratory of Tumor Immunology, Department of Internal Medicine, University of Torino. Head: Prof. Lina Matera, PhD).
- 2005-2009: PhD student, PhD thesis on "Immunoescape mechanisms of the prostatic tumor" (Laboratory of Tumor Immunology, Department of Internal Medicine, University of Torino. Head: Prof. Lina Matera, PhD).
- 2009-2010: Post-Doc fellowship to study the mechanisms of tumoral immunoevasion (Laboratory of Tumor Immunology, Department of Internal Medicine, University of Torino. Head: Prof. Lina Matera, PhD).
- 2010-2012: Post-Doc, co.co.pro. project contract to determine expression and functional of immunomodulatory molecules in the chronic lymphocytic leukemia microenvironment. (Immunogenetics Research Unit, Human Genetics Foundation (HuGeF), Torino. Supervisor: Silvia Deaglio, MD, PhD).
- 2012-2013: Post-Doc, co.co.pro. project contract from MERCK-SERONO to characterize responses to BRAF and MEK inhibitors in molecularly distinct melanomas. (Immunogenetics Research Unit, Human Genetics Foundation (HuGeF) Torino. Supervisor: Silvia Deaglio, MD, PhD)
- 2013-2014: Post-Doc, co.co.pro. project contract from Fondazione Ricerca Molinette Onlus (FIRMS), (Immunogenetics Research Unit, Human Genetics Foundation (HuGeF) Torino. Supervisor: Silvia Deaglio, MD, PhD).
- 2014-2016: Flow Cytometry and Cell Sorting Facility Manager, Human Genetics Foundation (HuGeF), Torino. Supervisor: Prof. Gianluca Severi, PhD.
- 2016-2018: Flow Cytometry and Research Logistician at IREC, UCL, Brussels. Supervisor: Prof. Jean-Luc Balligand, MD, PhD.
- 01 Oct 2018: qualification of Researcher level B (chargé de recherché niveau B) at UCLouvain.
- 01 Oct 2018: qualification of Principal Research Logistician at UCLouvain.

TEACHING ACTIVITY

- Academic years 2007-2008 and 2009-2010: courses in Molecular Pathology and Study of Cancer Vaccines in Solid Tumors (MED04) to the School of Biotechnology and Medical Biotechnology.
- June 2011: certified for "Cellular Immunotherapy" teaching (MED04).

- September 2015 and January 2016 course in “innovation of medical genetics in medicine” to degree in school of Nursing, University of Turin.
- March 2016 laboratory teaching to Medical Genetics of the University of Turin, Faculty of Medicine and Surgery.

MEMBERSHIP OF SCIENTIFIC SOCIETIES

Belgian Society for Advancement of Cytometry (BSAC)
American Association for Cancer Research
European Association for Cancer Research
Italian Society of Cancerology
Italian Society of Cytometry (GIC)

MAJOR COLLABORATIONS

- 2015: Dr. Andrea Pagnani, Hugef and Politecnico of Turin, Turin, Italy. (For the cell sorting and analyses of publication 4).
- 2014-2016: Dr. Daniela Taverna, University of Turin, Turin, Italy. (publication 6).
- 2013-2016 Dr. Mario Mandalà, Papa Giovanni XXII Hospital, Bergamo, Italy. (publications 8 and 11).
- 2013-2016: Dr. Daniela Massi, University of Florence, Florence, Italy. (publications 8 and 11).
- 2014: Dr.Franco Novelli, University of Turin, Turin, Italy. (For the multiparametric setting and analyses of publication 12).

PUBLICATIONS

Total Publications: 34
Total Publications with IF: 33
Total Publications as First Author: 7
Total IF (JCR): 210.944
Mean IF: 6.40
H-index: 16

1) Grasso D, Medeiros HCD, Zampieri LX, Bol V, Danhier P, van Gisbergen MV, Bouzin C, Brusa D, Grégoire V, Smeets H, Stassen APM, Dubois LJ, Lambin P, Dutreix M and Sonveaux P. Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Frontiers in Pharmacology 2020. **JCR 2019 4.400**

2) Trempolec N, Doix B, Degavre C, Brusa D, Bouzin C, Riant O, Feron O. Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma. Cancers (Basel). 2020 Feb 27;12(3). **JCR 2019 6.102**

3) Dei Zotti F, Verdoy R, Brusa D, Lobysheva II, Balligand JL. Redox regulation of nitrosyl-hemoglobin in human erythrocytes. Redox Biol. 2019. **JCR 2019 7.793**

4) Schoonjans CA, Joudiou N, Brusa D, Corbet C, Feron O, Gallez B. Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate. Cancer Lett. 2020;470:18-28. **JCR 2019 6.508**

5) André E, De Pauw A, Verdoy R, Brusa D, Bouzin C, Timmermans A, Bertrand L, Balligand JL. Changes of Metabolic Phenotype of Cardiac Progenitor Cells During Differentiation: Neutral Effect of Stimulation of AMP-Activated Protein Kinase. Stem Cells Dev. 2019;28(22):1498-1513. **JCR 2019 3.147**

6) Brusa D, Balligand JL. Classification of the Immune Composition in the Tumor Infiltrate. Methods Mol Biol. 2019;1979:305-315. **JCR 2019 10.71**

7) De Sanctis F, Sandri S, Martini M, Mazzocco M, Fiore A, Trovato R, Garetto S, Brusa D, Ugel S, Sartoris S. Hyperthermic treatment at 56 °C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. Vaccine 2018 Jun 14;36(25):3708-3716 **JCR 2017 3.235**

8) Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G. Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. Oncoimmunology. 2018 Feb 8;7(4):e1341032 **JCR 2017 7.719**

9) Tassone B, Saoncella S, Neri F, Ala U, Brusa D, Magnuson MA, Provero P, Oliviero S, Riganti C, Calautti E. Rictor/mTORC2 deficiency enhances keratinocyte stress tolerance via mitohormesis. Cell Death Differ. 2017 Apr;24(4):731-746. **JCR 2017 IF 8.339**

10) Bosia C, Sgrò F, Conti L, Baldassi C, Brusa D, Cavallo F, Di Cunto F, Turco E, Pagnani A and Zecchina R. RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear microRNA-dependent manner in single cells. Genome Biology 2017 Feb 20;18(1):37. **JCR 2017 IF 11.908**

11) Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016 Nov 22;1(1):47-61. **JCR 2016 IF 13.164**

12) Orso F, Quirico L, Virga F, Penna E, Dettori D, Cimino D, Coppo R, Grassi E, Elia AR, Brusa D, Deaglio S, Brizzi MF, Stadler MB, Provero P, Caselle M, Taverna D. miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer. Cancer Res 2016 Sep 1;76(17):5151-62. **JCR 2016 IF 9.122**

13) Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Pagnani A, Coscia M, D'Arena G, Mereu E, Piva R, Furman RR, Rossi D, Gaidano G, Terhorst C, Deaglio S. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. JCI 2016 Jan;126(1):181-94. **JCR 2016 IF 12.784**

14) Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 2015 Sep;26(9):1980-7. **JCR 2015 IF 9.269**

15) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015;125(1):111-23. **JCR 2015 IF 11.841**

16) Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D. The Krüppel-like factor 2 transcription factor is a novel tumor suppressor gene recurrently mutated in splenic marginal zone lymphoma. Leukemia 2015 Feb;29(2):503-74. **JCR 2015 IF 12.104**

17) Massi D*, Brusa D*, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Deaglio S§, Mandalà M§. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. *co-first and §co-last authors. Annals of Oncology, 2014;25(12):2433-42. **JCR 2014 IF 7.040**

18) Rolla S, Bardina B, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F, Clerico M. Th22 cells are expanded in multiple sclerosis and are resistant to IFNβ. Journal of Leukocyte Biology 2014;96(6):1155-64. **JCR 2014 IF 4.289**

19) Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D' Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S. HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism. Haematologica. 2014;99(5):888-96. **JCR 2013 IF 5.868**

20) Vaisitti T, Audrito V, Serra S, Bologna C, Arruga F, Brusa D, Buonincontri R, Gizdic B, Deaglio S. Multiple Metamorphoses Of CD38 From Prognostic Marker To Disease Modifier To Therapeutic Target In Chronic Lymphocytic Leukemia. Curr Top Med Chem. 2013;13(23):2955-64 Review. **JCR 2013 IF 3.453**

21) Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Ozren J, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S. The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953-63. **JCR 2013 IF 5.868**

22) Brusa D, Simone M, Gontero P, Spadi R, Racca P, Micari J, Degiuli M, Carletto S, Tizzani A, Matera L. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison. Int J Urol. 2013;20(10):971-8. **JCR 2013 IF 1.798**

23) Audrito V, Vaisitti T, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett. 2013;328(1):27-35. **JCR 2013 IF 5.016**

24) Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-52. **JCR 2011 IF 9.898**

25) Vaisitti T, Audrito V, Serra S, Bologna C, Brusa D, Malavasi F, Deaglio S. NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. FEBS Lett. 2011 Jun 6;585(11):1514-20. **JCR 2011 IF 3.538**

26) Brusa D, Carletto S, Cucchiarale G, Gontero P, Greco A, Simone M, Ferrando U, Tizzani A, Matera L. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes. Prostate. 2011;71:344-52. **JCR 2011 IF 3.485**

27) Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, Bosia A, Riganti C. Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med. 2011 Jul;15(7):1492-504. **JCR 2011 IF 4.125**

28) De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Molecular Cancer. 2009 Nov 19;8:108. **JCR 2009 IF 4.160**

29) Garetto S, Sizzano F, Brusa D, Tizzani A, Malavasi F, Matera L. Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation. Cytotherapy 2009;1-11:1090-100. **JCR 2009 IF 2.204**

30) Brusa D, Migliore E, Garetto S, Simone M, Material L. Immunogenicity of 56°C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. The Prostate 2009;69:1343-52. **JCR 2009 IF 3.081**

31) Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, Matera L. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine. 2008 Nov 25;26(50):6422-32. **JCR 2008 IF 3.298**

32) Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L and Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. Journal of Translational Medicine 2008, 6:25. **JCR 2008 IF 2.917**

33) Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther. 2007 Dec;6(12):1932-7. **JCR 2008 IF 2.761**

34) D'Hooghe E, Buttiglieri S, Bisignano G, Brusa D, Camussi G and Matera L. Apoptic renal carcinoma cells are best inducers of crosspresenting activity than their primary necrotic counterpart. Int. J. Imm. Pharm. 2007 Oct-Dec;20(4):707-17.

ORAL PRESENTATIONS

1) Brusa D, Bisignano B, Signorino E, Matera L. Phagocytosis of apoptotic/necrotic tumor by dendritic cells. Brallo di Pregola (PV) 12-15/6/06 20° nazional meeting "A.Castellani" of PhD student in biochemistry.
2) Brusa D, Bisignano B, Signorino E, Matera L. Suppression of anti-tumour lymphocyte response by a renal carcinoma cell line is reversed by death-associated stimulatory signals. Forli' 1-2/3/07 IV NCEV meeting.
3) Brusa D, Serra S, Bianco M, Coscia M, Rossi D, Gaidano G, Fedele G, Deaglio S. The PD-1/PD-L1 axis contributes to T cell dysfunction in Chronic Lymphocytic Leukemia. In: XII Congress of the Italian Society of Experimental Hematology. Roma, Italia, 17-19 Ottobre 2012, vol. 97(s2), p. s32-s32
4) Speaker to the Beckton Dickinson and Società italiana di Cancerologia Flow-cytometry course, Candiolo 18/03/2016. Talk on Multiparametric Phenotyping and Cell Sorting.

POSTER PRESENTATIONS

1) Brusa D, Bisignano B, Signorino E, Matera L. Generation of tumor-specific T CD8+ by crosspriming with dendritic cells. Brallo di Pregola (PV) 6-9/6/06 19° National meeting "A.Castellani" of PhD student in biochemistry.
2) Brusa D, Bisignano B, Signorino E, Matera L. Lymphocyte cross-priming is influenced by tumor death treatment and regulatory T lymphocytes. Granada, Spain 27-29/9/06 Sixth International conference on progress in vaccination against cancer PIVAC-6.
3) Brusa D, Simone M, Matera L. An immunosuppressive prostate tumor is turned into immunogenic by UVC and heat treatments inducing secondary necrosis. Berlin, Germany 13-16 September 2009. 2nd European Congress of Immunology (ECI2009).
4) Brusa D, Simone M, Greco A, Gontero P, Matera L. Mechanisms of Immunoevasion in patient with prostatic tumor Rimini 6/10/2009. 82° Nazional Congress SIU (Italian Society of Urology).
5) Brusa D, Serra S, Coscia M, Rossi D, Gaidano G, Inghirami G, Vaisitti T, Deaglio S. The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. In: European Congress of Immunology (ECI2012). Poster: The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. Glasgow 5-8 September 2012
6) Brusa D, Serra S, Bianco M, Coscia M, Rossi D, Gaidano G, Fedele G, Deaglio S. The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. In: XII Congress of the Italian Society of Experimental Hematology. Roma, Italia, 17-19 Ottobre 2012, vol. 97(s2), p. s32-s32
7) Brusa D, Serra S, Coscia M, Rossi D, Gaidano G, Inghirami G, Vaisitti T, Deaglio S. The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. In: 54th American Society of Hematology Annual Meeting and Exposition. Atlanta, GA, USA, 8-11 December 2012, vol. 120, p. 1778-1778
8) Brusa D, Massi D, Merelli B, Ciano M, Audrito V, Serra S, Baroni G, Nassini R, Minocci D, Cattaneo L, Carobbio A, Deaglio S, Mandalà M. PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressiveness. America Association for Cancer Research Meeting 2014. San Diego 5-9 April 2014.

ABSTRACT AS CO-AUTHOR

1) D'Hooghe E, Bisignano G, Brusa D, Bussolati B, Camussi G, Matera L. Cross-presentation of renal cancer-associated antigen by dendritic cells. 3rd National Conference SIICA, 19-23 April 2004, Ischia, Na

2) D'Hooghe E, Bisignano G, Buttiglieri S, Brusa D, Bussolati B, Camussi G, Matera L. T-lymphocyte priming by Dendritic cells loaded with apoptotic or necrotic renal cell carcinoma. Abstract. Journal of Immunotherapy. 27(6):S21, November/December 2004.
3) Matera L, Brusa D, D'Hooghe E, Bisignano B, Signorino E, Foglietta M, Massaia M. Cross-presentation of renal carcinoma cells is increased by death treatment and depletation of CD4+CD25+ lymphocytes. Abstract. Journal of Immunotherapy. 29(6):644-645, November/December 2006.
4) Serra S, Horenstein A, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson S, Gaidano G, Malavasi F, Deaglio S. CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. In: 53rd ASH Annual Meeting and Exposition. San Diego, CA; U.S.A., December 10-13 2011, vol. 118 (21), p. 621-621
5) Sara Serra, Davide Brusa, Alberto L. Horenstein, Claudio Tripodo, Tiziana Vaisitti, Valentina Audrito, Davide Rossi, Daniela Gottardi, Gianluca Gaidano, Fabio Malavasi and Silvia Deaglio. "Ectoenzyme-generated extracellular adenosine creates local conditions favoring growth and survival of CLL cells". 36th FEBS congress, June 25-30, 2011, Torino, Italy
6) Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Davide Rossi, Marta Coscia, Gianluca Gaidano, Cox Terhorst, Silvia Deaglio. "SLAMF1/CD150 is a signaling receptor in a subset of chronic lymphocytic leukemia cells". 99th Annual Meeting of the American Association of Immunologists, May 4-8, 2012, Boston, MA
7) Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Rossi D, Coscia M, Gaidano G, Terhorst C, Deaglio S (2012). SLAMF1/CD150 is a signaling receptor expressed by a subset of chronic lymphocytic leukemia patients characterized by a favorable prognosis. In: XII Congress of the Italian Society of Experimental Hematology. Roma, Italia, 17-19 Ottobre 2012, vol. 97(s2), p. s32-s32
8) Bologna C, Buonincontri R, Serra S, Vaisitti T, Audrito V, Brusa D, Rossi D, Coscia M, Gaidano G, Terhorst C, Deaglio S. SLAMF-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis. In: 54th American Society of Hematology Annual Meeting and Exposition. Atlanta, GA, USA, 8-11 December 2012, vol. 120, p. 1770-1770
9) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemiaAmerican Association for Cancer Research AACR Annual Meeting, 6-10 April, 2013, Washington, DC.
10) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia25th Pezcoller Symposium "METABOLISM AND TUMORIGENESIS". Trento, 20-22 June 2013
11) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemiaSummer Research Conferences FASEB "NAD metabolism & signaling", 14-19 July 2013, Itasca (Chicago), IL.
12) Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Davide Rossi, Marta Coscia, Gianluca Gaidano, Cox Terhorst, Silvia Deaglio. "SLAMF-1 is a signaling receptor modulating autophagy in a subset of chronic lymphocytic leukemia patients with a good prognosis." Autophagy, Inflammation and Immunity, February 17-22 2013 Montreal, QC, Canada.
13) Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Davide Rossi, Marta Coscia, Gianluca Gaidano, Cox Terhorst, Silvia Deaglio. "SLAMF-1 is a signaling receptor modulating autophagy in a subset of chronic lymphocytic leukemia patients with a good prognosis." 15th International Congress of Immunology, August 22-27 2013 Milan, Italy
14) Brusa D, Massi D, Merelli B, Ciano M, Audrito V, Serra S, Baroni G, Nassini R, Minocci D, Cattaneo L, Carobbio A, Deaglio S, Mandalà M. PD-L1 expression identifies a subpopulation of melanoma cells characterized by enhanced invasiveness and aggressiveness. 56th Annual Meeting of the Italian Cancer Society, Ferrara, 11-13 September 2014.
15) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 56th Annual Meeting of the Italian Cancer Society, Ferrara, 11-13 September 2014.

16) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemiaXIII SIES NATIONAL CONGRESS, 15-17 October 2014, Rimini, Italy.
17) Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Wolberger C, Raffaelli N and Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia56th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6-9, 2014, San Francisco, CA.
18) Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Davide Rossi, Marta Coscia, Gianluca Gaidano, Silvia Deaglio "SLAMF1/CD150 is a signaling receptor expressed by a subset of chronic lymphocytic leukemia patients characterized by a favorable prognosis." XIII National Congress SIES, 15-17 Ottobre 2014, Rimini, Italy
19) Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Davide Rossi, Marta Coscia, Gianluca Gaidano, Silvia Deaglio "SLAMF1/CD150 is a signaling receptor expressed by a subset of chronic lymphocytic leukemia patients characterized by a favorable prognosis." 56th Annual Meeting of the Italian Cancer Society SIC, 1-13 September 2014, Ferrara, Italy
20) S. Serra, R. Buonincontri, V. Audrito, T. Vaisitti, D. Brusa, S.C. Robson, S. Deaglio. Role of extracellular adenosine in shaping the leukemic niche: the example of CD73 expression in chronic lymphocytic leukemia. Purines 2014 – Nucleotides, Nucleosides and Nucleobases, International Conference of Signalling, Drugs and Targets, 23-27 July 2014, Bonn, Germany.
21) S. Serra, R. Buonincontri, D. Brusa, V. Audrito, T. Vaisitti, M. Coscia, L. Laurenti, G. D'Arena, D. Rossi, G. Gaidano, S.C. Robson, S. Deaglio. Cooperation between adenosinergic and hypoxic signals in shaping chronic lymphocytic leukemia microenvironment. 56th Annual Meeting of the Italian Cancer Society, 11-13 September 2014, Ferrara, Italy.
22) S. Serra, R. Buonincontri, D. Brusa, V. Audrito, T. Vaisitti, M. Coscia, L. Laurenti, G. D'Arena, D. Rossi, G. Gaidano, S.C. Robson, S. Deaglio. Cooperation between adenosinergic and hypoxic signals in shaping chronic lymphocytic leukemia microenvironment. XIII SIES National Congress, 15-17 October 2014, Rimini, Italy.
23) S. Serra, D. Brusa, R. Buonincontri, V. Audrito, T. Vaisitti, S.C. Robson, S. Deaglio. Cooperation between adenosinergic and hypoxic signals in shaping chronic lymphocytic leukemia microenvironment. AACR, 18-22 April 2015, Philadelphia, PA, USA.

Total Abstracts: 31

COURSES ATTENTED

- II° workshop in cellular separation techniques: negative, positive, magnetic and by gradient. CBA-San Martino di Genova, October 2003.
- Stage at the Laboratory of Immunology, Interfakultäres Institut für Zellbiologie, Eberhard Karls Universität Tübingen (Germany); July-September 2006. Learned techniques used for detecting antigen-specific T lymphocytes by cytometry such as tetramer/pentamer multicolor staining, intracellular cytokine staining and CSFE-based proliferation assay.
- IV Interactive course in cytometry (SIICA), organized by Prof. Andrea Cossarizza at Policlinico of Modena, March 2007.
- Course in cytometry at laboratory of Neuroimmunology of Prof. Giovanna Borsellino and Luca Battistini, Santa Lucia foundation, Rome, June 2007.
- Training course on FACSCANTOII cytometer at BD Biosciences, Buccinasco (Milan) 7-9 October 2008.
- GIC training course on cell sorting (RICS), Istituto Ricerche Farmacologiche Mario Negri, Milan, 12/04/2011.
- Training course on FACSARIAIII cell sorter certified by BD Biosciences at the Molecular Biotechnology Centre, Turin, 10-12 July 2-3 October 2013.
- XXXII National Training course and Conference of Cytometry (GIC), Urbino 22-26 September 2014.
- XXXIII National Conference of Cytometry (GIC), Lucca 22-25 September 2015.
- XXXIV National Training course and Conference of Cytometry (GIC), Urbino 20-23 September 2016

- XXXV National Conference of Cytometry (GIC), Paestum 3-6 October 2017.
- BD Discovery Day conference, Gilze (NL), 20/03/2018
- Belgian Society for Advancement of Cytometry (BSAC) Annual meeting, Hof ter Musschen, Brussels, 4 October 2018.

RESPONSABILITIES AS PLATFORM MANAGER

- Update of standard operating procedures (SOPs)
- Promote the Platform by organizing technological seminars with flow cytometry international Companies
- Organize Trainings with the release of a Certification recognized for University credits to students
- Provide consultation of experiment settings, protocols, data acquisition, data interpretation
- Maintain an optimal set up of in vitro/in vivo experiments to obtain good flow cytometric results
- Experience an ever-increasing expertise in order to cover all the various requests of researchers
- Develop new techniques or instrumentation for the Platform
- Data backup
- Administrative functions: reporting, billing, rate setting, budget development
- Organize the annual meetings of the Management Committee and Users Committee to check the goals achieved and eventually make ameliorations

TECHNICAL COMPETENCES

- Experienced user of FACSAriaIII cell sorter and FACSCantoII cytometer
- Flow cytometry to determine cell subpopulations, cell cycle, viability (apoptosis assays), cytotoxicity, proliferation
- Cell separation with magnetic beads conjugated antibodies (MACS)
- Experience in optical and fluorescent microscopy, Immunofluorescence (immunocytochemistry)
- Immunohistochemistry
- Cell Culture of both adherent and non-adherent cell lines
- Peripheral blood separation on Ficol gradient
- Cryopreservation of cells and biopsies
- Induction of differentiation with growth factors: generation of Dendritic Cells
- Stimulation of lymphocyte populations with autologous Dendritic Cells presenting tumor antigens
- Phagocytosis assay
- ELISA and ELISpot assays
- Mixed Lymphocyte Reaction
- Proliferation assays using 3H-thymidine and CFSE labeling
- Cytotoxicity assay using 51Cr-release
- Western Blot
- DNA and RNA extractions
- PCR, quantitative real time PCR
- Transfection and infection techniques

PERSONAL SKILLS

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2
French	B1	B2	B1	B1	B1
Arabic	A1	A1	A1	A1	A1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Mother tongue: Italian

COMPUTER COMPETENCES

Microsoft Office Word, Excel, Power Point; Adobe Photoshop, Illustrator; CorelDraw; GraphPad Prism; analysis programs for flow cytometry Diva 6 and FlowJo (Windows) and Cell Quest (Machintosh); ImageJ, LeicaQFluo, ImageQuant

OTHER INFORMATION

Participation in the Piedmont Start-Cup 2010 with the idea: “Dendritic cell technology for tumor treatment”, reaching the top three in September 2010.

Bruxelles, 2020 February 20th